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Conclusion: MBG underestimates MVO after an optimal revascularization
in AMI compared to CMR. This study suggests the superior accuracy of
delayed enhanced magnetic resonance (DEMR) over MBG for the assessment
of myocardial reperfusion injury which is needed in clinical trials where the
principal endpoint is the reduction of infarct size (IS) and MVO. 
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The CYP2C19*2 genetic variant is known to contribute to low responsive-
ness to clopidogrel treatment, leading to a higher rate of cardiovascular events.
Systematic identification of the 2C19*2 carriers to predict the individual
patient’s response to clopidogrel is a matter of debate.
Data of the VASP-02 study comparing patients’ responsiveness to 75 and
150 mg/day maintenance dose of clopidogrel (Aleil et al., J Am Coll Cardiol
Intv 2008) were reanalyzed by determining the 2C19*2 carrier status of the
patients. Platelet reactivity index (PRI) was determined using the VASP
method. A PRI>69 % defines low responsiveness to clopidogrel.
In the 37 non responder patients, 42.4 % were 2C19*2 carriers versus 22.0
% in the responder patients (p=0.022). After multivariate analysis, 2C19*2
polymorphism and high body weight were two independent predictors of high
PRI (odds ratio [95% confidence interval] 3.39 [1.06-10.84] p=0.039 and 3.14
[1.19-8.30] p=0.021) respectively. Increasing the maintenance dose of clopido-
grel from 75 to 150 mg/day in non responder patients resulted in a significant
decrease of PRI from 76.4±4.6 to 62.8±10.4 % (p<0.01) in 2C19*2 carriers
and from 76.1±5.3 to 60.8±13.4 % (p<0.01) in non carriers. The mean
decrease of PRI after doubling the dose was not significantly different between
carriers and non carriers of the genetic variant (-13.6±9.3 and -15.3±11.8 %
p=0.39, respectively).
CYP2C19*2 is an important determinant of the responsiveness to clopido-
grel while other independent factors such as body weight also are involved.
Hyporesponsiveness in 2C19*2 carriers can be easily overcome by doubling
the maintenance dose of clopidogrel. Thus, combined functional pharmacody-
namic monitoring and genetic determination of CYP profile should help
improve patient’s responsiveness to clopidogrel.
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Introduction: Numerous biological studies have reported inter-individual
variability in platelet response to clopidogrel with clinical relevance. High
Post treatment platelet reactivity (ADP-induced aggregation >70%) has been
proposed to define Non response to clopidogrel. We assessed in clopidogrel
non responders undergoing elective percutaneous coronary intervention (PCI)
the benefit of adjusted antiplatelet therapy with glycoprotein IIbIIIa (GPII-
bIIIa) antagonist administration during PCI for one month clinical outcome.
Methods and Results: 149 clopidogrel non-responders referred for elec-
tive PCI were prospectively included and randomized to “conventional group”
(n=75) or “active group” with GPIIbIIIa antagonist (n=74). All patients
received 250 mg aspirin and 600 mg clopidogrel before PCI and platelet tes-
ting. The rate of CV events at one month was significantly lower in the “active
group” than in the “conventional group”: 19% (n=14) vs. 40% (n=30),
p=0.006, [OR (95%CI): 2.8(1.4-6.0)]. No patient in either group had post pro-
cedural TIMI major bleeding or required transfusions.
Conclusion: The present study suggested benefit of tailored antiplatelet
therapy during elective PCI with GPIIbIIIa antagonist for clopidogrel non res-
ponders without increased bleeding risk.
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Objectives: To determine if the speed of response to clopidogrel loading
predicts the final degree of response to clopidogrel.
Background: Fast inhibition of platelet aggregation is important in the set-
ting of ACS and PCI, but its relation to the final degree of inhibition is not
well established.
Methods: We performed a post-hoc analysis of ALBION, which included 103
NSTE-ACS patients randomised to 300, 600 or 900mg LD of clopidogrel. Early
kinetic profiles of ADP 20μmol/l Maximal Platelet Aggregation (MPA) and del-
taMPA (with baseline sample as reference) were studied, with 8 time points within
the 24 hours following loading. Low response was defined as deltaMPA<10%
p=0.006
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over the first 24 hours, fast response as deltaMPA≥10% within the first hour after
loading (the others being slow responders), and high post-treatment platelet reacti-
vity (HPPR) as MPA≥56.56% (fourth quartile). Inflammatory markers (PAC1 and
P-selectin) and VASP were also evaluated according to onset of action.
Results: 55% of patients were slow responders. Non current smoking and
BMI ≥ 25 kg/m_ were associated with slower and lower response. HPPR was
more frequent in slow responders (28% vs 14% p<0.0001). There was a dose
effect relationship on deltaMPA, with a trend for faster onset of platelet inhi-
bition in the 900 mg LD group. Slow responders had slower and lower
decrease of PAC1 and P-selectin, and higher VASPindex at 6 hours (76.5% vs
66.4%, p=0.019) and 24 hours (70.3% vs 61.5%, p=0.049).
Conclusions: Slow response to clopidogrel is a reliable marker of low res-
ponse at 24 hours and HPPR. Whether early detection and correction of slow
clopidogrel response is clinically relevant remains to be demonstrated. 
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Is it long-term (> 12 months) dual antiplatelet treatment necessary in
diabetic patients treated with drug-eluting stents?
Vassilis Voudris, Panagiotis Karyofillis, Sophia Thomopoulou, Dennis V
Cokkinos
Onassis Cardiac Surgery Center, Cardiology Dpt, Athens, Grèce
Background: Despite encouraging short-term results with drug-eluting
stents (DES) in diabetes mellitus (DM) patients (pts) with coronary artery
disease, the long-term safety is not clear. We investigated the influence of
long-term (> 12 months) dual antiplatelet treatment (APLT) with aspirin and
clopidogrel on clinical outcome in DM pts treated with DES.
Methods: The study included 552 consecutive DM pts (male 81%, mean age
65+9 years) that had been treated with DES and received dual APLT treatment for
12 months. Long-term clinical follow-up (FU) (mean time 30.4 + 11.6 months),
obtained in 545/552 (99%) of them; 419 (77%) pts were on dual APLT (group A)
and 126 (23%) on single APLT (group B). Major adverse cardiovascular event
(MACE) on clinical FU was considered death (D), myocardial infarction (MI),
percutaneous or surgical revascularization (REV), cerebrovascular accident
(CVA), and hard end-points (HDP) was considered D, MI and CVA. Late stent
thrombosis (LST) was defined as angiographic documentation of stent occlusion
associated with an acute ischemic event, unexplained sudden D or MI not clearly
attributable to another coronary lesion > 12 months post-procedure.
Results: Unstable angina at presentation was more frequent in group A pts
(36% vs. 26%, p<0.05).The incidence of LST was 2.1% in group A and 0.8%
in group B pts (p:ns); no difference was observed according to diabetic treat-
ment (insulin vs. non-insulin dependent). At FU D was observed in 4.8% vs.
2.4%, MI 1.9% vs. 0.8%, and HDP in 8.4% vs. 4% between pts in group A
and B respectively (p:ns). The rate of any REV and MACE was higher in pts
in group A (20.3% vs. 6.3 %, and 26.7% vs. 11.1%, p<0.001); this difference
was only observed in non-insulin-dependent pts. In a multivariate model ejec-
tion fraction <40% was predictor for LST (HR 14.5, 95% CI 3.9-49.4,
p<0.001), and D/MI (HR 3.61, 95% CI 1.7-7.5, p=0.001), and multivessel
disease for MACE (HR 2.0,95% CI 1.27-3.15, p=0.003).
Conclusion: Dual APLT > 12 months in DM pts treated with DES implan-
tation is not associated with better clinical outcome or lower risk of LST. 
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Primary coronary angioplasty (PCA) of unprotected left main coronary
artery (LM) in patients (pts) with cardiogenic shock (CS) is a high-risk proce-
dure, carrying a high morbi-mortality. 
Accordingly we aimed to assess the prevalence, clinical presentation, the-
rapeutic workout and in-hospital and long-term prognosis of pts presenting
with CS due to TIMI flow 0-1 LM thrombosis.
Over a 6-years period, and out of a prospective cath-lab database of 6062
files, 17 cases of CS secondary to LM thrombosis were identified and con-
firmed by reanalysis of angiograms. Therapeutic management and in-hospital
outcome were obtained from medical files and prospective follow-up was
obtained.
The study population consisted in 13 men (76%) with a mean age of 64±16
years, corresponding to a prevalence of 0.28 % of pts proposed for coronary pro-
cedure. Clinical presentation was an ACS with and without persistent ST-eleva-
tion in 11 (65%) and 6 cases (35%) respectively. Five patients (29%) received
pre-hospital thromboysis, which failed to achieved reperfusion in all cases.
Twelve patients (71%) undergone mechanical support (intra-aortic balloon pum-
ping alone in 55%, extracorporeal life support alone in 5%, and both in 45%).
The majority of PCA were performed with bare metal stent (n=14, 82%), under
GPIIbIIIa antagonists in 8 cases, and instrumental thrombectomy in 3 cases. In-
hospital death occurred in 5 pts (29%). At mean follow-up of 23 months (100%
completed) survival rate was 53% for entire cohort and 75% among discharged
pts. Most patients were in NYHA class I (7/9), with averaged left ventricular
ejection fraction of 50+17%. One pts was implanted with a Thoratec device and
is awaiting heart transplantation, and one is in terminal heart failure.
LM occlusion with CS has a very high mortality rate. However, PCA in such
setting with use of aggressive mechanical life support carries an acceptable level
of major adverse coronary event at medium and long-term prognosis. 
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Background: In ACS patients, presence of a peripheral arterial disease
(PAD) or a low ankle brachial index (ABI) is associated with a higher CV risk
in either symptomatic or asymptomatic PAD patients than ACS patients
without PAD.
Objective: To determine the frequency and describe symptomatic and
asymptomatic PAD patients, diagnosed by clinical examination and ABI
measurement, in French population with recent history of ACS.
Methods: A 2-stage observational survey was conducted by 422 office-
based cardiologists: 1) a registry part to provide a nationally representative
overview and to estimate the prevalence of PAD and proportion of normal or
low ABI in the overall.
2) a detailed part to asses and compare patients issued from registry with
symptomatic or asymptomatic PAD and without PAD.
Results: 374 office based cardiologists recorded in the registry 2030
patients with a recent history of ACS and selected 1135 patients for the
detailed part of the study.
Main characteristics of the registry patients were: mean age 66 years, 75%
male, 30.3% STEMI, 22.7% NSTEMI and 47.1% UA. The prevalence of PAD
in the registry population was 35.9% and between them 401 (55.1%) were
symptomatic: intermittent claudication (321), history of angioplasty or bypass
(221), amputations (12). Mean value of ABI measurement in the registry was
0.93 CI [0.92-0.94] with 32.3% less than 0.9.
In the detailed part of the study, the mean age was 65.7 years and 77.7%
of patients were male. ACS characteristics: STEMI 32.1%, NSTEMI 22.4%
and UA 45.5%. 624 patients were selected without PAD and 511 with PAD.
Within these patients, 55.4% were symptomatic: intermittent claudication
(20.3%), had a history of angioplasty or bypass (12.6%), or amputations
(0.4%). Mean value of ABI for 1131 patients in the detailed study was 0.9
[0.89-0.91] and 42% had a low ABI (<0.9).
Conclusions: PAD is highly prevalent (35.9%) in patients with recent his-
tory of ACS and almost one half of these patients are asymptomatic.
